Capricorn Fund Managers Ltd Has $301,000 Stock Position in Glaukos Corporation $GKOS

Capricorn Fund Managers Ltd lowered its position in Glaukos Corporation (NYSE:GKOS) by 95.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,800 shares of the medical instruments supplier’s stock after selling 57,200 shares during the period. Capricorn Fund Managers Ltd’s holdings in Glaukos were worth $301,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in GKOS. AustralianSuper Pty Ltd grew its stake in Glaukos by 10.8% in the third quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock valued at $36,685,000 after acquiring an additional 43,750 shares during the period. SG Americas Securities LLC raised its position in shares of Glaukos by 460.8% during the fourth quarter. SG Americas Securities LLC now owns 60,232 shares of the medical instruments supplier’s stock worth $6,801,000 after purchasing an additional 49,492 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Glaukos by 32.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 355,279 shares of the medical instruments supplier’s stock worth $39,336,000 after purchasing an additional 87,781 shares during the period. TD Asset Management Inc acquired a new stake in shares of Glaukos during the third quarter worth about $1,157,000. Finally, DNB Asset Management AS lifted its holdings in shares of Glaukos by 11.9% during the 4th quarter. DNB Asset Management AS now owns 82,320 shares of the medical instruments supplier’s stock valued at $9,295,000 after purchasing an additional 8,770 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. boosted their price objective on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Wells Fargo & Company raised their target price on shares of Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Citigroup raised their target price on shares of Glaukos from $140.00 to $162.00 and gave the stock a “buy” rating in a report on Thursday, June 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a report on Tuesday, April 21st. Finally, Needham & Company LLC upped their price target on shares of Glaukos from $136.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $149.17.

Insider Transactions at Glaukos

In other news, COO Joseph E. Gilliam sold 19,573 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the completion of the transaction, the chief operating officer directly owned 73,419 shares of the company’s stock, valued at $10,538,563.26. This trade represents a 21.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Alex R. Thurman sold 10,000 shares of Glaukos stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $140.00, for a total transaction of $1,400,000.00. Following the completion of the sale, the chief financial officer owned 43,681 shares in the company, valued at $6,115,340. This trade represents a 18.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 41,273 shares of company stock worth $5,832,003. 5.90% of the stock is currently owned by insiders.

Glaukos Stock Performance

Shares of Glaukos stock opened at $139.87 on Wednesday. The firm has a market cap of $8.21 billion, a price-to-earnings ratio of -42.64 and a beta of 0.82. The stock’s 50-day moving average is $128.02 and its 200-day moving average is $118.68. Glaukos Corporation has a one year low of $73.16 and a one year high of $148.11. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.12. The company had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.Glaukos’s revenue for the quarter was up 41.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.22) earnings per share. Equities analysts predict that Glaukos Corporation will post -0.57 earnings per share for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.